US2020247887A1PendingUtilityA1

Anti-cd79b antibodies and immunoconjugates and methods of use

Assignee: GENENTECH INCPriority: Jul 16, 2007Filed: Oct 11, 2019Published: Aug 6, 2020

Est. expiryJul 16, 2027(~1 yrs left)· nominal 20-yr term from priority

Inventors:Yvonne Chen Mark S. Dennis David Dornan Kristi Elkins Jagath Reddy Junutula Andrew Polson Bing Zheng

G01N 33/5759G01N 33/575A61K 47/68033A61K 47/68031A61K 47/6803C07K 16/2896C07K 16/2803A61K 47/6849A61K 39/39558A61K 2039/505C07K 2317/24C07K 2317/565A61K 39/3955C07K 2317/56C07K 2317/55G01N 2333/70596C07K 2317/92G01N 33/68C07K 2317/567C07K 2317/40A61K 31/537A61K 38/05Y02A50/30A61P 31/00A61K 47/6811C12N 15/85C07K 16/3061A61K 45/06A61K 51/1027C07K 2317/73C07K 2317/34A61K 39/395A61P 43/00A61K 47/6867A61P 35/02A61K 47/50A61P 37/00C07K 16/28A61P 35/00G01N 33/57492

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Claims

exact text as granted — not AI-modified

1 - 16 . (canceled) 
     
     
         17 . A humanized anti-CD79b antibody wherein monovalent affinity of the antibody to human CD79b is substantially the same as monovalent affinity of a murine antibody comprising a light chain and heavy chain variable sequence as depicted in  FIGS. 7A-7  (SEQ ID NO: 10) and  FIGS. 8A-8  (SEQ ID NO: 14). 
     
     
         18 - 258 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.